Committee Print

[Showing the text of H.R. 4284 as forwarded by the Subcommittee on Health on April 25, 2018]

115TH CONGRESS 1ST SESSION

H. R. 4284

To establish a Federal Coordinator within the Department of Health and Human Services, and for other purposes.

IN THE HOUSE OF REPRESENTATIVES

NOVEMBER 7, 2017

Mr. Latta (for himself, Mr. McKinley, Mr. Barton, and Mr. Johnson of Ohio) introduced the following bill; which was referred to the Committee on Energy and Commerce

A BILL

To establish a Federal Coordinator within the Department of Health and Human Services, and for other purposes.

- 1 Be it enacted by the Senate and House of Representa-
- 2 tives of the United States of America in Congress assembled,
- 3 SECTION 1. SHORT TITLE.
- 4 This Act may be cited as the "Indexing Narcotics,
- 5 Fentanyl, and Opioids Act of 2018" or the "INFO Act".

1	SEC. 2. ESTABLISHMENT OF SUBSTANCE USE DISORDER IN-
2	FORMATION DASHBOARD.
3	(a) In General.—Not later than 60 days after the
4	date of the enactment of this Act, the Secretary of Health
5	and Human Services shall, in consultation with the Direc-
6	tor of National Drug Control Policy, establish and periodi-
7	cally update a public information dashboard that—
8	(1) coordinates information on programs within
9	the Department of Health and Human Services re-
10	lated to the reduction of opioid abuse and other sub-
11	stance use disorders;
12	(2) provides access to publicly available data
13	from other Federal agencies; State, local, and Tribal
14	governments; nonprofit organizations; law enforce-
15	ment; medical experts; public health educators; and
16	research institutions regarding prevention, treat-
17	ment, recovery, and other services for opioid use dis-
18	order and other substance use disorders
19	(3) provides comparable data on substance use
20	disorder prevention and treatment strategies in dif-
21	ferent regions and population of the United States;
22	(4) provides recommendations for health care
23	providers on alternatives to controlled substances for
24	pain management, including approaches studied by
25	the National Institutes of Health Pain Consortium

1	and the National Center for Complimentary and In-
2	tegrative Health; and
3	(5) provides guidelines and best practices for
4	health care providers regarding treatment of sub-
5	stance use disorders.
6	(b) Controlled Substance Defined.—In this
7	section, the term "controlled substance" has the meaning
8	given that term in section 102 of the Controlled Sub-
9	stances Act (21 U.S.C. 802).
10	SEC. 3. INTERAGENCY SUBSTANCE USE DISORDER COORDI-
11	NATING COMMITTEE.
12	(a) Establishment.—Not later than three months
13	after the date of the enactment of this Act, the Secretary
14	of Health and Human Services (in this section referred
15	to as the "Secretary") shall, in consultation with the Di-
16	rector of National Drug Control Policy, establish a com-
17	mittee, to be known as the Interagency Substance Use
18	Disorder Coordinating Committee (in this section referred
19	to as the "Committee"), to coordinate all efforts within
20	the Department of Health and Human Services con-
21	cerning substance use disorder.
22	(b) Membership.—
23	(1) Federal members.—The Committee shall
24	be composed of the following Federal members (or
25	the designees of such members):

1	(A) The Secretary, who shall service as the
2	Chair of the Committee.
3	(B) The Attorney General of the United
4	States.
5	(C) The Secretary of Labor.
6	(D) The Secretary of Housing and Urban
7	Development.
8	(E) The Secretary of Education.
9	(F) The Secretary of Veterans Affairs.
10	(G) The Commissioner of Social Security.
11	(H) The Assistant Secretary for Mental
12	Health and Substance Use.
13	(I) The Director of the Centers for Disease
14	Control and Prevention.
15	(J) The Director of the National Institutes
16	of Health and the Directors of such national re-
17	search institutes of the National Institutes of
18	Health as the Secretary determines appropriate.
19	(K) The Administrator of the Centers for
20	Medicare & Medicaid Services.
21	(L) The Director of National Drug Control
22	Policy.
23	(M) Representatives of other Federal agen-
24	cies that serve individuals with substance use
25	disorder.

1	(2) Non-federal members.—The Committee
2	shall be composed of a minimum of 17 non-Federal
3	members appointed by the Secretary, of which—
4	(A) at least two such members shall be an
5	individual who has received treatment for a di-
6	agnosis of an opioid use disorder;
7	(B) at least two such members shall be an
8	individual who has received treatment for a di-
9	agnosis of a substance use disorder other than
10	an opioid use disorder;
11	(C) at least two such members shall be a
12	State Alcohol and Substance Abuse Director;
13	(D) at least two such members shall be a
14	representative of a leading research, advocacy,
15	or service organization for adults with sub-
16	stance use disorder;
17	(E) at least two such members shall—
18	(i) be a physician, licensed mental
19	health professional, advance practice reg-
20	istered nurse, or physician assistant; and
21	(ii) have experience in treating indi-
22	viduals with opioid use disorder or other
23	substance use disorders;
24	(F) at least one such member shall be a
25	substance use disorder treatment professional

1	who is employed with an opioid treatment pro-
2	gram;
3	(G) at least one such member shall be a
4	substance use disorder treatment professiona
5	who has research or clinical experience in work
6	ing with racial and ethnic minority populations
7	(H) at least one such member shall be a
8	substance use disorder treatment professiona
9	who has research or clinical mental health expe-
10	rience in working with medically underserved
11	populations;
12	(I) at least one such member shall be a
13	State-certified substance use disorder peer sup-
14	port specialist;
15	(J) at least one such member shall be a
16	drug court judge or a judge with experience in
17	adjudicating cases related to substance use dis-
18	order;
19	(K) at least one such member shall be a
20	law enforcement officer or correctional officer
21	with extensive experience in interacting with
22	adults with a substance use disorder; and
23	(L) at least one such member shall be an
24	individual with experience providing services for

1	homeless individuals and working with adults
2	with a substance use disorder.
3	(c) Terms.—
4	(1) In General.—A member of the Committee
5	appointed under subsection (b)(2) shall be appointed
6	for a term of three years and may be reappointed
7	for one or more three-year terms.
8	(2) Vacancies.—A vacancy on the Committee
9	shall be filled in the same manner in which the origi-
10	nal appointment was made. Any individual appointed
11	to fill a vacancy for an unexpired term shall be ap-
12	pointed for the remainder of such term and may
13	serve after the expiration of such term until a suc-
14	cessor has been appointed.
15	(d) Meetings.—The Committee shall meet not fewer
16	than two times each year.
17	(e) Duties.—The Committee shall—
18	(1) monitor opioid use disorder and other sub-
19	stance use disorder research, services, and support
20	and prevention activities across all relevant Federal
21	agencies, including coordination of Federal activities
22	with respect to opioid use disorder and other sub-
23	stance use disorders;
24	(2) evaluate the effectiveness of Federal grants
25	and programs for the prevention and treatment of,

1	and recovery from, opioid use disorder and other
2	substance use disorders;
3	(3) review substance use disorder prevention
4	and treatment strategies in different regions and
5	populations in the United States and evaluate the
6	extent to which Federal substance use disorder pre-
7	vention and treatment strategies are aligned with
8	State and local substance use disorder prevention
9	and treatment strategies;
10	(4) make recommendations to the Secretary re-
11	garding any appropriate changes with respect to the
12	activities and strategies described in paragraphs (1)
13	through (3);
14	(5) make recommendations to the Secretary re-
15	garding public participation in decisions relating to
16	opioid use disorder and other substance use dis-
17	orders and the process by which public feedback can
18	be better integrated into such decisions; and
19	(6) make recommendations to ensure that
20	opioid use disorder and other substance use disorder
21	research, services, and support and prevention activi-
22	ties of the Department of Health and Human Serv-
23	ices and other Federal agencies are not unneces-
24	sarily duplicative.
25	(f) Annual Report.—

1	(1) In general.—Not later than one year
2	after the date of the enactment of this Act, and an-
3	nually thereafter for the life of the Committee, the
4	Committee shall publish on the public information
5	dashboard established under section 2(a) a report
6	summarizing the activities carried out by the Com-
7	mittee pursuant to subsection (e), including any
8	findings resulting from such activities.
9	(2) RECOMMENDATION FOR COMMITTEE EX-
10	TENSION.—After the publication of the second re-
11	port of the Committee under paragraph (1), the Sec-
12	retary shall submit to Congress a recommendation
13	on whether or not the operations of the Committee
14	should continue after the termination date described
15	in subsection (i).
16	(g) Working Groups.—The Committee may estab-
17	lish working groups for purposes of carrying out the duties
18	described in subsection (e). Any such working group shall
19	be composed of members of the Committee (or the des-
20	ignees of such members) and may hold such meetings as
21	are necessary to enable the working group to carry out
22	the duties delegated to the working group.
23	(h) Federal Advisory Committee Act.—The
24	Federal Advisory Committee Act (5 U.S.C. App.) shall
25	apply to the Committee only to the extent that the provi-

- 1 sions of such Act do not conflict with the requirements
- 2 of this section.
- 3 (i) Sunset.—The Committee shall terminate on the
- 4 date that is six years after the date on which the Com-
- 5 mittee is established under subsection (a).

Amend the title so as to read: "A bill to establish a substance use disorder information dashboard within the Department of Health and Human Services, and for other purposes.".